News Conference News ACC 2025 RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI Michael O'Riordan April 02, 2025
News Conference News CRT 2025 Need for Rethink of Discharge Medications After LAA Closure? EMERGE L.A. McKeown March 12, 2025
News Daily News Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD Todd Neale December 06, 2024
News Conference News THT 2024 Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients Michael O'Riordan March 07, 2024
News Conference News ISC 2024 Tirofiban May Cut Early Worsening After Acute Ischemic Stroke Todd Neale February 13, 2024
News Conference News ESOC 2023 ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy Todd Neale May 25, 2023
News Daily News Anatomic Disease After PCI Linked With Worse Outcomes: VA CART Michael O'Riordan December 22, 2022
News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022
News Conference News ESC 2022 Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke Todd Neale August 28, 2022
News Conference News ISC 2022 CHOICE: Intra-arterial tPA Enhances Benefit of Stroke Thrombectomy Todd Neale February 11, 2022
News Conference News ISC 2022 ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis Todd Neale February 10, 2022
News Daily News DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis L.A. McKeown January 20, 2022
News Conference News TCT 2021 LAA Closure Feasible in Patients With Thrombus: Registry Michael O'Riordan October 13, 2021
News Daily News Observational Study Supports Continuing Oral Anticoagulation During PCI Michael O'Riordan April 06, 2021
News Daily News Thrombus Burden Greater in STEMI Patients With COVID-19 Michael O'Riordan July 20, 2020